Zibotentan
As of the edition of 20 October 2026, Zibotentan is a small molecule: in active development; acts on EDNRA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 32, 6 stopped early
- Disease areas
- Urinary and reproductive; Cancer; Pregnancy and women's health; Digestive system; Skin and connective tissue; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EDNRA | Endothelin-1 receptor | P25101 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 12 | 12 | 0 | 0 |
| Phase 2 | 15 | 9 | 1 | 5 |
| Phase 3 | 4 | 2 | 1 | 1 |
| All trials | 32 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2003 to now |